Efung Capital overview
Efung Capital contact information
Offices
505 China resources building, Keyuan south road, Nanshan district, Shenzhen, 2666, ChinaContacts
| Name | Job title | Location | |
|---|---|---|---|
 Mr. Pai Zhu | Job titleManaging Partner | LocationShenzhen, China | Email  ----------- |
| Ms. Ruina Wang | Job titlePartner | LocationShenzhen, China | Email --------- |
Stories that mention Efung Capital
Harbour BioMed pulls in $75m
Cambridge, Massachusetts-based Harbour BioMed, a biopharmaceutical company, has secured $75 million in financing.
Tactiva Therapeutics inks $35 mln Series A
Tactiva Therapeutics, a cancer immunotherapy company, has secured $35 million in Series A financing. Panacea Healthcare Partners led the round with participation from other investors that included Vi Ventures and Efung Capital.
KBP Biosciences snags $76 mln Series A
Princeton, New Jersey-based KBP Biosciences, a biotech company focused on developing medicines in areas of unmet medical need, has secured $76 million in Series A financing. Advantech Capital and SDIC Venture Capital led the round with participation from Sangel Capital, Ping An Ventures, Bay City Capital GF XINDE Life Science Investment Fund, Efung Capital, CASH Capital, Cowin Capital Group, Korea Investment Partners and Elite Capital.
Centrexion rakes in $67 mln Series D in NEA-led round
Boston-based Centrexion Therapeutics Corporation, a developer of treatments for chronic pain, has closed $67 million in Series D financing. New Enterprise Associates led the round with participation from other investors that included Quan Capital, ArrowMark Partners, certain investment funds advised by Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital and Efung Capital. In conjunction with the funding, Centrexion has appointed Dr. Sara Nayeem, a partner at NEA, and Dr. Stella Xu, a managing director at Quan Capital, to its board of directors. Leerink Partners LLC was financial adviser on the transaction.